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The role of telemedicine in the delivery of health care in the 
COVID-19 pandemic
On 11 March 2020, the World Health Organization declared the 
coronavirus disease 2019 (COVID-19), a pandemic. Recently, 
Hermans et al1 outlined the challenges the COVID-19 pandemic 
pose for the bleeding disorder community. The general response 
to the pandemic has included increased measures focused on per-
sonal hygiene, social distancing, symptom monitoring, early diagno-
sis, patient isolation, shelter in place and public health quarantine. 
Accordingly, such measures have led to concerns over how to main-
tain access to haemophilia treatment products and to the specialized 
integrated care medical follow-up within the haemophilia treatment 
centres (HTCs). As part of the medical response to disasters such as 
a worldwide pandemic, telemedicine has emerged as one proposed 
solution to address this type of global challenge.2
The information age brought tremendous advancements in tele-
communications including telemedicine, the ability for healthcare 
professionals (HCPs) to directly interact with patients in separate 
locations. Originally conceived of to access patients in remote areas 
distant from the HCP, telemedicine has evolved, first as a conve-
nience for patients (and possibly HCPs) but today amid a global 
pandemic, is a necessary way of delivering health care to all but 
the sickest of people in the current environment of shelter in place 
bringing medical care to patients while attempting to reduce the 
transmission of COVID-19 among patients, families and clinicians.3 
It allows moving health care from the hospital to the home, similar 
to how many now conduct their banking, not needing to travel to a 
physical bank to conduct business.4
Telemedicine may include a variety of technologies to securely 
deliver remote health care including: live (synchronous) videoconfer-
encing, typically a two-way audiovisual link between a patient and 
an HCP in different locations; audio-only visits via patient portals 
and messaging technologies; remote patient-monitoring tools; and 
store-and-forward technologies that collect images and data to be 
transmitted at a later time (eg educational materials).5 These tech-
nologies offer several possible advantages including: the ability to 
quickly ask and receive answers to questions; more timely diagnosis 
and institution of treatment for some conditions such as stroke; pa-
tients have access to medical specialists as well as a general HCP; 
the possibility of enhanced patient privacy; reduced costs and in-
creased convenience; and reduced need for physical contact limiting 
potential infectious exposures. The potential disadvantages of tele-
medicine include the need for technical training on the part of the 
HCP and, to some degree, the patient; the necessary equipment to 
conduct the tele-visit; the possibility of a reduction in continuity of 
care like the retail healthcare movement; and last but certainly, not 
the least of the disadvantages is the inability to conduct a physical 
examination.5
While sustaining optimal care during a pandemic is challeng-
ing, we can draw on prior experience. In 2012, the NHF-McMaster 
Guidelines on Care Models for Haemophilia Management6 suggested 
that an optimal integrated care model include a haematologist, a 
specialized haemophilia nurse, a physical therapist, a social worker 
and round-the-clock access to a specialized coagulation laboratory 
be part of the integrated care team. While it may seem daunting, 
there is significant precedent for remote care delivery in haemo-
philia management. The impact of telemedicine, outreach clinics and 
other remote care delivery systems as an alternative/add-on to inte-
grated care was identified as a priority within the guidelines.
In 2013, the US National Hemophilia Program Coordinating 
Center (NHPCC) conducted a survey of Hemophilia Treatment 
Centers (HTC) assessing gaps in care and resources needed to sup-
port care.7 Compared to the previous survey, there was a marked 
increase in those identifying geographical access as a technical as-
sistance need. Subsequently, one of four projects of national signif-
icance funded by the NHPCC evaluated how HTCs could provide 
care remotely to rural areas using telemedicine.8 The pilot study 
demonstrated a high level of patient satisfaction with the telemed-
icine approach and significant cost savings, both in terms of cost of 
travel and time away from work. While telemedicine outreach clinics 
have long existed and been utilized in a number of HTCs to resolve 
geographical access challenges the pilot project results published in 
2018 demonstrated that, while not without challenges, telemedicine 
is especially well suited for patients with chronic disorders such as 
haemophilia.8
Concerns raised with telemedicine have primarily been related 
to privacy and data protection due to the risk for inadvertent disclo-
sure of sensitive information.9 As part of the US national response 
to the COVID-19 national public health emergency, the Office for 
Civil Rights (OCR) has stated that it will not impose penalties on phy-
sicians using telehealth in the event of non-compliance with regu-
latory requirements as outlined in the Health Insurance Portability 
and Accountability Act (HIPAA).10 Despite this change, it is important 
that HCPs obtain consent from patients for the telemedicine visit.
Patient acceptance of, and satisfaction with, telemedicine has 
generally been favorable.5 In one study examining the management 
of osteoporosis,11 participants expressed comfort with the use of 
technology and believed that the quality of care was comparable to 
     |  e231LETTER TO THE EDITOR
in-person visits. Benefits included the convenience and a reduced 
burden of travel and costs. Perceived barriers this study identified 
included lack of follow-up and compliance with recommended tests 
and studies. Prior experience does not allow us to conclude that 
telemedicine can deliver outcomes similar to in-person clinical en-
counters. During the pandemic, telemedicine will be utilized to de-
liver both routine care and emergency management. In addition to 
clinical outcomes, it will be important to document and monitor pa-
tient-important outcomes, for example impact on functional status 
along with feasibility and acceptability. We can anticipate many les-
sons applicable to future healthcare delivery will be learned during 
the pandemic. As noted by Hermans et al, within this rapidly evolv-
ing healthcare environment, HTCs must adapt to the new reality 
of telemedicine. However, ultimately clinical trials may be required 
to understand whether telemedicine is to be a long-term and suit-
able alternative for in-person delivery of care for people living with 
bleeding disorders. The task for telemedicine providers will be to 
tackle these challenges head-on. We need more research demon-
strating that telemedicine improves patient-centred outcomes and 
that it can do so efficiently—not just for individual encounters but at 
the population level, without leading to overuse.12
In summary, in the context of a pandemic, telemedicine has the 
potential to increase convenience, improve access, improve patient 
safety and better manage costs and limit exposures to patients and 
HCPs while reducing the burden on healthcare facilities allowing 
them to deal with the sickest patients. In a more general sense, 
widespread implementation of telemedicine will not only enhance 
the direct care of patients with bleeding disorders but will enable 
more people, especially those living in underserved areas, to receive 
specialty haematology care.8 With the recent trends in the health-
care marketplace seeing an increase in enrolment in high-deduct-
ible consumer-driven health plans, rewarding providers for value 
requires moving encounters to lower cost options while maintaining 
quality care delivery.
The pandemic has catalysed HCPs and patients to try telemedi-
cine at an unprecedented level.13 How we embed the learnings from 
our experiences during the pandemic in the future delivery of care 
remains to be seen. However, there is little doubt that the way care is 
provided by HCPs and sought by patients in the future will be trans-
formed. Telehealth will be a critical pillar enabling the cost-effective 
and safe provision of value-based care. Telemedicine is a good op-
tion for patients and HCP's for situations where the medical care 
infrastructure remains intact and HCPs are available to interact with 
patients to deliver care remotely.14
DISCLOSURE S
The authors stated that they had no interests which might be per-




1National Hemophilia Foundation, New York, NY, USA
2Rush University, Chicago, IL, USA
3Institute for Policy Advancement Ltd, Washington, DC, USA
4Department of Health Research Methods, Evidence, and 
Impact, McMaster University, Hamilton, ON, Canada
5University of Michigan, Ann Arbor, MI, USA
Correspondence
Leonard A. Valentino, National Hemophilia Foundation, 
New York, NY, USA.
Email: lvalentino@hemophilia.org
ORCID
Leonard A. Valentino  https://orcid.org/0000-0002-7927-6418 
Mark W. Skinner  https://orcid.org/0000-0002-0934-0680 
Steven W. Pipe  https://orcid.org/0000-0003-2558-2089 
R E FE R E N C E S
 1. Hermans C, Weill A, Pierce GF. The COVID-19 pandemic: new 
global challenges for the hemophilia community. Haemophilia. 
2020. https://onlin elibr ary.wiley.com/doi/pdf/10.1111/hae.14001 
[Epub ahead of print].
 2. Lurie N, Carr BG. The role of telehealth in the medical response to 
disasters. JAMA Intern Med. 2018;178(6):745-746.
 3. Ohannessian R, Duong TA, Odone A. Global telemedicine im-
plementation and integration within health systems to fight the 
COVID-19 pandemic: a call to action. JMIR Public Health Surveill. 
2020;6(2):e18810.
 4. Dorsey ER, Topol EJ. Telemedicine 2020 and the next decade. 
Lancet. 2020;395(10227):859.
 5. Almathami HKY, Win KT, Vlahu-Gjorgievska E. Barriers and facilita-
tors that influence telemedicine-based, real-time, online consulta-
tion at patients' homes: systematic literature review. J Med Internet 
Res. 2020;22(2):e16407.
 6. Pai M, Key NS, Skinner M, et al. NHF-McMaster guideline on care 
models for haemophilia management. Haemophilia. 2016;22(Suppl 
3):6-16.
 7. Expanding telemedicine to medical homes for comprehensive care 
delivery. 2020. https://athn.org/what-we-do/nhpcc/ telem edici 
ne.html. Accessed April 15, 2020
 8. Kulkarni R. Use of telehealth in the delivery of comprehensive care 
for patients with haemophilia and other inherited bleeding disor-
ders. Haemophilia. 2018;24(1):33-42.
 9. Callens S. Telemedicine and European law. Med Law. 
2003;22(4):733-741.
 10. Civil Rights, HIPAA, and the Coronavirus Disease 2019 (COVID-19). 
In: Rights OfC, ed. OCR Issues Bulletin on Civil Rights Laws and 
HIPAA. Washington, DC: HHS; 2020.
 11. Palcu P, Munce S, Jaglal SB, et al. Understanding patient experiences 
and challenges to osteoporosis care delivered virtually by telemed-
icine: a mixed methods study. Osteoporos Int. 2020;31(2):351-361.
 12. Kahn JM. Virtual visits–confronting the challenges of telemedicine. 
N Engl J Med. 2015;372(18):1684-1685.
 13. Coombs B. Telehealth visits are booming as doctors and patients 
embrace distancing amid the coronavirus crisis. CNBC. 2020. 
Available at https://www.cnbc.com/2020/04/03/teleh ealth -visit 
s-could -top-1-billi on-in-2020-amid-the-coron aviru s-crisis.html
 14. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-
19. N Engl J Med. 2020;382(18):1679-1681.
